Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

[1]  J. Stasch,et al.  Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. , 2012, American journal of physiology. Heart and circulatory physiology.

[2]  A. Abbate,et al.  Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. , 2011, American journal of physiology. Heart and circulatory physiology.

[3]  L. Potter.  Natriuretic peptide metabolism, clearance and degradation , 2011, The FEBS journal.

[4]  L. Agulló,et al.  cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion. , 2011, Journal of molecular and cellular cardiology.

[5]  J. Stasch,et al.  Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  J. Beavo,et al.  Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy , 2010, Proceedings of the National Academy of Sciences.

[7]  P. Dent,et al.  Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction , 2010, Proceedings of the National Academy of Sciences.

[8]  Anindita Das,et al.  Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect , 2010, Journal of Pharmacology and Experimental Therapeutics.

[9]  D. Kass,et al.  Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. , 2010, Journal of molecular and cellular cardiology.

[10]  Z. Giricz,et al.  Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation , 2010, Basic Research in Cardiology.

[11]  F. Hofmann,et al.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes , 2010, Proceedings of the National Academy of Sciences.

[12]  A. Abbate,et al.  Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide , 2009, Circulation.

[13]  J. Corbin,et al.  cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium , 2009, Journal of Pharmacology and Experimental Therapeutics.

[14]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[15]  J. Cartledge,et al.  Differences in side‐effect duration and related bother levels between phosphodiesterase type 5 inhibitors , 2009, BJU international.

[16]  J. Downey,et al.  BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. , 2009, European heart journal.

[17]  Lei Xi,et al.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[18]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[19]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[20]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[21]  Anindita Das,et al.  Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β* , 2008, Journal of Biological Chemistry.

[22]  K. Black,et al.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model , 2008, Brain Research.

[23]  C. Des Rosiers,et al.  Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency , 2008, Proceedings of the National Academy of Sciences.

[24]  Anindita Das,et al.  Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[25]  P. Ferdinandy,et al.  Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling , 2007, British journal of pharmacology.

[26]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[27]  F. Salloum,et al.  Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. , 2007, Journal of molecular and cellular cardiology.

[28]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Iα Attenuates Necrosis and Apoptosis Following Ischemia/Reoxygenation in Adult Cardiomyocyte* , 2006, Journal of Biological Chemistry.

[29]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[30]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[31]  J. Downey,et al.  Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts , 2006, Basic Research in Cardiology.

[32]  F. Salloum,et al.  Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. , 2006, Journal of molecular and cellular cardiology.

[33]  Shufeng Zhou,et al.  Role of Hydrogen Sulfide in the Cardioprotection Caused by Ischemic Preconditioning in the Rat Heart and Cardiac Myocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[34]  N. Maeda,et al.  The role of natriuretic peptides in cardioprotection. , 2006, Cardiovascular research.

[35]  M. Beckerle,et al.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. , 2005, The Journal of clinical investigation.

[36]  J. Tidball,et al.  Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. , 2005, Human molecular genetics.

[37]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[38]  P. Fisher,et al.  Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. , 2005, Vascular pharmacology.

[39]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[40]  B. Zhu,et al.  Suppression of cyclic GMP‐specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells , 2005, Journal of cellular biochemistry.

[41]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[42]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[43]  D. Koesling,et al.  NO activation of guanylyl cyclase , 2004, The EMBO journal.

[44]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Left Ventricular Remodeling After Myocardial Infarction in Mice , 2004, Circulation.

[45]  Anindita Das,et al.  Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. , 2004, American journal of physiology. Heart and circulatory physiology.

[46]  P. Ferdinandy,et al.  B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. , 2003, American journal of physiology. Heart and circulatory physiology.

[47]  F. Salloum,et al.  Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase–Dependent Pathway in Mouse Heart , 2003, Circulation research.

[48]  J. Finsterer,et al.  The Heart in Human Dystrophinopathies , 2003, Cardiology.

[49]  David P. Rotella,et al.  Phosphodiesterase 5 inhibitors: current status and potential applications , 2002, Nature Reviews Drug Discovery.

[50]  F. Salloum,et al.  Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. , 2002, American journal of physiology. Heart and circulatory physiology.

[51]  R. Bolli,et al.  Role of Cyclic Guanosine Monophosphate in Late Preconditioning in Conscious Rabbits , 2002, Circulation.

[52]  J. Tidball,et al.  A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice , 2001, The Journal of cell biology.

[53]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  I. Goldstein,et al.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial , 2001, International Journal of Impotence Research.

[55]  K. Nakao,et al.  Dwarfism and early death in mice lacking C-type natriuretic peptide , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  U. Walter,et al.  Regulation of Human Endothelial Cell Focal Adhesion Sites and Migration by cGMP-dependent Protein Kinase I* , 2000, The Journal of Biological Chemistry.

[57]  F. Hofmann,et al.  Rising behind NO: cGMP-dependent protein kinases. , 2000, Journal of cell science.

[58]  R. Rakhit,et al.  Nitric oxide-induced cardioprotection in cultured rat ventricular myocytes. , 2000, American journal of physiology. Heart and circulatory physiology.

[59]  H. Weiss,et al.  Cyclic GMP reduces ventricular myocyte stunning after simulated ischemia-reperfusion. , 1999, Nitric oxide : biology and chemistry.

[60]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[61]  S. Kaul,et al.  Writing Group Members , 2022 .

[62]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[63]  M. Kuhn,et al.  ANP protects against reoxygenation-induced hypercontracture in adult cardiomyocytes. , 1997, The American journal of physiology.

[64]  R. Penner,et al.  Transfected cGMP-dependent protein kinase suppresses calcium transients by inhibition of inositol 1,4,5-trisphosphate production. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Boyd,et al.  Effects of first‐dose doxorubicin on cardiac rhythm as evaluated by continuous 24‐hour monitoring , 1985, Cancer.

[66]  J. Downey,et al.  Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. , 2004, American journal of physiology. Heart and circulatory physiology.

[67]  S. Sano,et al.  Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. , 2004, The Annals of thoracic surgery.

[68]  S. Kaul,et al.  ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. , 1999, Journal of the American College of Cardiology.

[69]  A. Szewczyk,et al.  ATP-sensitive K+ channel in mitochondria. , 1993, Acta biochimica Polonica.